The National Institutes of Health (NIH) awarded a phase I grant to Tango Biosciences in January 2021. This award will support a collaborative effort that generates recombinant antibodies and antibody-like reagents for 6 SARS-CoV-2 viral proteins. These reagents will aid scientists in understanding the function of these viral proteins inside infected cells. Such information may lead to the identification of new drug targets.
NIH SBIR Award
More News and Events
-
News
Michael Scholle Appointed CEO of Tango Biosciences
Co-founder Brian Kay to assume Chief Scientific Officer, focused on scientific innovation and operations CHICAGO–Tango Biosciences, Inc., the premier research partner for custom affinity reagents by phage display, announced Michael Scholle, MS, MBA as Chief Executive Officer effective immediately. Scholle is one of three co-founders of Tango Biosciences and an active board member. This transition enables president […]
-
Event
SLAS 2025
Visit Tango Biosciences at the 2025 SLAS International Conference & Exhibition! January 25-29, 2025 | San Diego, CA Booth #2317 Plus, mark your calendar to join our Solution Spotlight presentation: Rapid Phage Display Solutions ideal for SLAS: Screening Ligands for Affinity and Selectivity Tuesday, January 28 | 5:00 PM – 5:20 PM PST
-
News
Tango Biosciences publishes work on SARS-CoV-2 virus
Tango Biosciences scientists, in collaboration with colleagues from B2S Life Sciences, LifeTein, and Euprotein, publish a scientific report on generating recombinant affinity reagents (monobodies) to the receptor binding domain (RBD) of the SARS-CoV-2 virus, which is responsible for the COVID-19 pandemic. Soluble forms of the monobodies bound to several different preparations of the RBD and […]